%PDF-1.6
%
2 0 obj
<>
endobj
96 0 obj
<>stream
2017-10-05T07:29:14-05:00
Canon
2017-10-05T07:33:19-05:00
2017-10-05T07:33:19-05:00
uuid:bb1b849b-5db1-42c3-bc41-8c40e2d413a9
uuid:ec27b295-6a00-42e7-b721-8860e34bd14b
application/pdf
endstream
endobj
3 0 obj
<>
endobj
97 0 obj
<>
endobj
98 0 obj
<>
endobj
99 0 obj
<>
endobj
126 0 obj
<>
endobj
177 0 obj
<>
endobj
209 0 obj
<>
endobj
217 0 obj
<>
endobj
255 0 obj
<>
endobj
222 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 248 0 R/XObject<>>>/Type/Page>>
endobj
223 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 253 0 R/XObject<>>>/Type/Page>>
endobj
256 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 268 0 R/XObject<>>>/Type/Page>>
endobj
257 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 273 0 R/XObject<>>>/Type/Page>>
endobj
258 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 278 0 R/XObject<>>>/Type/Page>>
endobj
259 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 283 0 R/XObject<>>>/Type/Page>>
endobj
260 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 288 0 R/XObject<>>>/Type/Page>>
endobj
261 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 293 0 R/XObject<>>>/Type/Page>>
endobj
262 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 298 0 R/XObject<>>>/Type/Page>>
endobj
263 0 obj
<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/Subtype 303 0 R/XObject<>>>/Type/Page>>
endobj
303 0 obj
<>stream
Presentar la sguenteinformacin debdamentedocumentada al trmino dela administracin deltratamiento y alsegumiento con el AnexoN' 07 de la Drectva N'003-rETSt-ESALUO-2016.
DTCTAMEN PRELtMINAR DE Er/ALUAclN DE TEcNorociA sANtrARtA N" o44sDEpFyoT$oETstETStmlT"EFICACIA Y SEGURIOAD OL USOADALIMUMAB EN ELRATAMIENTO DE PACIEIJIES CONARTRITIS PSORIASICA REFRACTARIOS ATERAPACONVENCIONALYAETANERCEPIE INFLIXIMAB'
'1. ACR 20, 50 y 702. PSARC3. Eventos adversos4. Evaluacin de dactilitis y entesitis
45
endstream
endobj
304 0 obj
<>/Filter/CCITTFaxDecode/Height 2338/Length 10328/Name/Obj54/Subtype/Image/Type/XObject/Width 1653>>stream
̭I3:KLeGDpg'[ѡva#1GbӃ<=o
[D}#WWW^zv`.X}z/X?[Ϟ?_7\}T,Wa/צE|{Y
r?kD7D7O]=H XqPwsMgDe"2 """""~vwwvz8r+{KM}ߜr _qL:8>XTVo""KJu|g+DDDCE4ulVS#LWտ/_-/XM0v'~
(ivR/].^"""""""""ӻUlU_"f+DXDDD4""!iTDDDDDDDu1L
adE-2: 2||p#ȧgF|N=J=ޛi#Cxjh3h2#=@瑢1abIIΛmg3ô/ǣcGGXY[_,[mj ^K^_҂#xD_]o_/_hxycwK}z)a_`&
.+^v[mkN?Z_Oѭ}q}zX
?z]ua?KdLWQ^H[ +ovZO>?
w{ߤ_D:iz**D[G"Iauw}""""""""Bf]jئ).خMmvJȏm/'"""" wiئ+":*faaUO1IqaZ#`fhh3r9qL#:r53_>|zs oKyGсMtt=ӻ]m;a O"qȎU|?
}ޖooI$@->z=eƗ{kp?A">UN)w"oU}/m/T.:W_[#w4EG0D{DGn¥:w^K"DvOE_ۺmg/mj">"߿=z4ocv.G7n;{>}Ebl0
/.m7{ϟoVl|3G[mOhX[)O>G'qIk8!M?DDDDDDDDD[QN
9JÐk*P(dqT\2 'bH_?V n9CQd6 #Hm:/G6G?}k_~/fJ2Q)_mzu2s!ƯA d{-4BCG#z0͙~!K$
4-44^<~]}6DRPJ&HwjXN-Bү:ީn
iNQD&'|H|7ƿim'NxL4NII|OOq_%T~ޗ__㯎m/q~n}ii%g&މIw߶jݯ
kMF_6+[[]UrMi{V8/ح
s_ d[
ڭ߭`X+"""!ɼ4lka4 L&('iGK?_Ȁ7d;2BI2v
ρ""D/D vU3'#8#HAf3̎AlSCSS$ 440a"ӋL!ٗF#OMA(qDRoD&;_OMSAZzOO]4]I9'Nנui0Z*SMD'ߓ?
txA0Dyׯ
?|sHa>:zBW_?m~?_G'uG(~r+Ҝ}7mNQ;wMGXLcGy68_mko_ !
]#8l_1xe&S_b#DA""zt=ovu"""" 0*wvi_&xa}&E *wI)I;&~d!':HEmwp Aov[D|Ԡ}#k
D{ni\"[>sp-&&zIIs몫ſ$]I!6%:n~)
Q/Ҷ]<:i84H%A.}N"!LTDZSV9bW*z
h)Tc{j{!
֙M#R
һgR<)f3om_h#~
amq ˈphgXEmjjg0@~)[`"aRl/oDݢC5Smׄ\k6NAy8pzz"!A>qA7Q릟ND'DG/J}
S}" (/}ǧű ___tݵJ(_[/OW'H}!/uٷZ_kf~~p|lVƻ
l']C}O쓶F=kݭrDDC1uU^^|DDDDB!LZv$w""""=[
=ĖqJlXAOOv;\^`7O(SkmoUs_ +d{D} f60#zOAgO2Iߏݏi
S#8FS;x""8g%qz
a<0@όжdz.1ڦzh0|PMpM4 3`Ee&KGL$J GD%$OOOH')WOWTm DN2oג} KҿX1v*om&m"v[4;_оKozWvoW"
T7OqoO+_0#%?뿺F');zFn!ʝ+XUڲ"-vߜ~m8/chAv?lqkuDӖ`#{ 25|8)Of
uT!ih2Ck+Bii_bB.A^""""Da &餶C`C!m65ء~FV)tXawHNh!b}ۍ8蹈Kƚn,}limgVfgGuIwp2 ]ܱگ7@ gdA;qJAwo얣3f!iO*QJWaW(x^4A&EbWlAt< itgjOJ`[_>9j#].9|Nk\[9a2v/IS{e㌝rݢoDߧ㏭pdq~>B elwڤm#8عfdkq2%m$cqǿM?W>:TAgK<3[ϑ!VD.gwqw[1zW{_"᯦hi0Aً1$G>dxaÃ(4m%\x_: [|Z 7fQoDݢc?]Af#c;Ja#ⶂ_O>{_nn
s[mQ1ߪaw0 ~t&8㮝u?i:=_{m5wrUk_|}xZk6`zn!un?16' /{^;R|_3]tǰPA }KmlUY=]~{>)8]/ͽ=}˼r_uޫ|0cGBTq|S
o_mm-qalu/_6&GɼA>k*{1ZfT/
EhBX6S'i??{[V}mUol?
&a4i{M5o/
/mm]]+ZC&"wح88aKVaqDD0C5&NӲ(*+Fqxra;M0kbBӰK_kΌ!s?t|H36HfyhTEH.ddi'
5N?Q7rX?m'7NOǭq&X톓{; NoǻYԳ13EK8'ޱ?